51,250 Zoetis Inc. $ZTS Shares Purchased by Heathbridge Capital Management Ltd.

Heathbridge Capital Management Ltd. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 34.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 201,975 shares of the company’s stock after buying an additional 51,250 shares during the period. Zoetis comprises approximately 4.7% of Heathbridge Capital Management Ltd.’s holdings, making the stock its 12th largest holding. Heathbridge Capital Management Ltd.’s holdings in Zoetis were worth $14,104,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. lifted its stake in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. State Street Corp increased its position in Zoetis by 1.8% during the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after purchasing an additional 343,322 shares during the period. Deutsche Bank AG increased its position in Zoetis by 5.8% during the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares during the period. Bank of America Corp DE increased its position in Zoetis by 7.3% during the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after purchasing an additional 327,313 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Zoetis by 7.7% in the 2nd quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock valued at $305,559,000 after purchasing an additional 303,395 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. William Blair cut Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Stifel Nicolaus decreased their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, BTIG Research dropped coverage on shares of Zoetis in a research note on Friday, October 30th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $93.79.

Zoetis Trading Up 0.0%

Shares of NYSE:ZTS opened at $83.19 on Wednesday. The business’s 50-day moving average is $75.27 and its 200 day moving average is $93.22. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49. The firm has a market capitalization of $34.38 billion, a P/E ratio of 13.71, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm’s revenue was down .2% compared to the same quarter last year. During the same period last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts predict that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is currently 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.